Multiple reports have demonstrated that BTK is a critical kinase for CLL development.38 Ibrutinib, a BTK inhibitor, is currently used in the clinic for CLL treatment.30 Moreover, we have demonstrated a synergistic reduction in cell viability following combined treatment with CNL and ibrutinib. Here, BTK is linked to B-cell chronic lymphocytic leukemia.